Olokizumab

Drug Profile

Olokizumab

Alternative Names: Anti-IL6 - UCB; CDP-6038

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Developer R-Pharm; UCB
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 04 Jul 2017 Phase-III clinical trials in Rheumatoid arthritis in USA, Taiwan, South Korea, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Poland, United Kingdom, Germany (SC) (NCT03120949)
  • 06 Mar 2017 Phase-III clinical trials in Rheumatoid arthritis in Lithuania (EudraCT2015-005309-35)
  • 03 Mar 2017 Phase-III clinical trials in Rheumatoid arthritis (Combination therapy) in Latvia (SC) (EudraCT2015-005307-83)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top